Page 120 - Read Online

Page 20 of 23 Thonglert et al. Hepatoma Res 2023;9:40 https://dx.doi.org/10.20517/2394-5079.2023.47

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer
2022;161:108-18. DOI
2. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev
Gastroenterol Hepatol 2020;17:557-88. DOI PubMed PMC
3. Primrose JN, Fox RP, Palmer DH, et al; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer
(BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73. DOI
4. Zheng X, Chen B, Wu JX, et al. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic
cholangiocarcinoma that adhere to major vessels. Cancer Manag Res 2018;10:3973-81. DOI PubMed PMC
5. Jiang W, Zeng ZC, Tang ZY, et al. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and
concurrent lymph node metastases. J Cancer Res Clin Oncol 2010;136:1323-31. DOI
6. Sur MD, In H, Sharpe SM, et al. Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma. Ann
Surg Oncol 2015;22:2209-17. DOI
7. Lin YK, Hsieh MC, Wang WW, et al. Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: chemotherapy
alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy. Radiother Oncol 2018;128:575-83. DOI PubMed
8. Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive
treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008;72:1495-501. DOI PubMed
9. Kim YS, Oh SY, Go SI, et al. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar
cholangiocarcinomas. Cancer Chemother Pharmacol 2017;79:99-106. DOI
10. Hammad AY, Berger NG, Eastwood D, et al. Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? the
impact of surgical margins and lymph node status on survival. Ann Surg Oncol 2016;23:912-20. DOI
11. Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an astro clinical practice
guideline. Pract Radiat Oncol 2022;12:28-51. DOI
12. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI
13. Oh D, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid
2022;1:EVIDoa2200015. DOI
14. Oh DY, He AR, Qin S, et al. 56P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo
(PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol 2022;33:S565-6.
DOI
15. Yamashita S, Koay EJ, Passot G, et al. Local therapy reduces the risk of liver failure and improves survival in patients with
intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients. Cancer 2017;123:1354-62. DOI PubMed
PMC
16. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 2021;397:428-44. DOI PubMed
17. Verma V, Kusi Appiah A, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Lin C. Chemoradiotherapy versus chemotherapy alone for
unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. J Gastrointest Oncol
2018;9:527-35. DOI PubMed PMC
18. Brunner TB, Blanck O, Lewitzki V, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of
patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019;132:42-7. DOI
19. De B, Tran Cao HS, Vauthey JN, et al. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: patterns of care
and survival in the United States. Cancer 2022;128:2529-39. DOI PubMed PMC
20. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients
with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8. DOI
PubMed PMC
21. Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J
Cancer 2015;6:1099-104. DOI PubMed PMC
22. Smart AC, Goyal L, Horick N, et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic
cholangiocarcinoma. Ann Surg Oncol 2020;27:1122-9. DOI
23. Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with
inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016;34:219-26. DOI PubMed
PMC